The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| EVOK | +150.8% | -97.54% | -52.34% | -99% |
| S&P | +12.94% | +86.25% | +13.25% | +303% |
Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It also develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $4.28M | 61.4% |
| Gross Profit | $4.18M | 64.0% |
| Gross Margin | 97.62% | 1.5% |
| Market Cap | $7.75M | 98.6% |
| Market Cap / Employee | $2.58M | 0.0% |
| Employees | 3 | -25.0% |
| Net Income | -$1.16M | 11.9% |
| EBITDA | -$1.14M | 11.5% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $11.58M | 2.1% |
| Accounts Receivable | $3.19M | 57.7% |
| Inventory | 0.6 | 21.6% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $0.05M | 0.0% |
| Short Term Debt | $5.07M | 1.3% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -35.07% | 20.8% |
| Return On Invested Capital | -264.81% | 17.5% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$0.52M | 36.2% |
| Operating Free Cash Flow | -$0.52M | 36.2% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.90 | 0.58 | 0.66 | 1.70 | 29.23% |
| Price to Sales | 0.64 | 0.60 | 0.52 | 0.88 | 13.95% |
| Price to Tangible Book Value | 0.90 | 0.58 | 0.66 | 1.70 | 29.23% |
| Enterprise Value to EBITDA | 1.56 | 0.36 | 0.19 | -5.49 | 2075.98% |
| Return on Equity | -240.1% | -108.8% | -152.9% | -134.9% | -61.45% |
| Total Debt | $5.16M | $5.14M | $5.13M | $5.11M | 2.25% |
No podcast episodes available.
No transcripts available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
